Hemmo Pharmaceuticals Pvt. Ltd.

Hemmo Pharmaceuticals Pvt. Ltd. is an Indian company specializing in pharmaceutical development and production, offering innovative solutions to enhance health outcomes through advanced therapies. Founded in 1972 and headquartered in Mumbai, India, Hemmo Pharmaceuticals Pvt.

Ltd. is engaged in pharmaceutical development and manufacturing. It was fully acquired by Piramal Pharma Ltd for INR 7. 75 billion in March 2021.

The acquisition is expected to enhance operational capacity with the addition of over 250 employees, including Ph. D. scientists. The company has not undergone any significant pivots in its business strategy since its inception.

Hemmo Pharmaceuticals offers a range of pharmaceutical products and services that focus on innovative drug formulations and development. Their product portfolio addresses various therapeutic areas, enhancing the efficiency of healthcare delivery. The company primarily serves healthcare providers and institutions, ensuring that its products meet the rigorous demands of modern healthcare. For the year 2021, Hemmo Pharmaceuticals reported a revenue of INR 17,092,645.

90 and an EBITDA of INR 7,915,384. 70, demonstrating a solid financial foundation built on a diverse revenue model. Hemmo Pharmaceuticals is focused on expanding its product offerings and enhancing market presence following its recent acquisition by Piramal Pharma Ltd. The company plans to introduce new pharmaceutical products targeting unmet medical needs.

Additionally, there are strategic plans to expand into international markets, particularly in North America and Europe, to leverage growth opportunities. The recent funding from Piramal Pharma Ltd will be utilized to support these initiatives and further invest in research and development, aiming for a more robust portfolio by the end of 2022.